AU4608296A - Methods and compositions for treatment of solid tumors in vivo - Google Patents

Methods and compositions for treatment of solid tumors in vivo

Info

Publication number
AU4608296A
AU4608296A AU46082/96A AU4608296A AU4608296A AU 4608296 A AU4608296 A AU 4608296A AU 46082/96 A AU46082/96 A AU 46082/96A AU 4608296 A AU4608296 A AU 4608296A AU 4608296 A AU4608296 A AU 4608296A
Authority
AU
Australia
Prior art keywords
vivo
compositions
treatment
methods
solid tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46082/96A
Inventor
Francis J Burrows
Thomas W. Dubensky Jr.
Timothy C Fong
Douglas J. Jolly
John M Polo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Publication of AU4608296A publication Critical patent/AU4608296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU46082/96A 1994-12-30 1995-12-22 Methods and compositions for treatment of solid tumors in vivo Abandoned AU4608296A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36857494A 1994-12-30 1994-12-30
US368574 1994-12-30
PCT/US1995/016855 WO1996021416A2 (en) 1994-12-30 1995-12-22 Methods and compositions for treatment of solid tumors in vivo

Publications (1)

Publication Number Publication Date
AU4608296A true AU4608296A (en) 1996-07-31

Family

ID=23451821

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46082/96A Abandoned AU4608296A (en) 1994-12-30 1995-12-22 Methods and compositions for treatment of solid tumors in vivo

Country Status (4)

Country Link
EP (1) EP0802801A2 (en)
JP (1) JP2001520503A (en)
AU (1) AU4608296A (en)
WO (1) WO1996021416A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509578A (en) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター Cancer treatment using malignant cells
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
ATE340259T1 (en) * 1996-07-16 2006-10-15 Archibald James Mixson CATIONIC VEHICLE: DNA COMPLEXES AND THEIR USE IN GENE THERAPY
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
EP2298900A1 (en) * 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
FR2757178B1 (en) * 1996-12-13 1999-03-05 Centre Nat Rech Scient USE OF A VECTOR EXPRESSING DNA POLYMERASE BETA AS A MEDICAMENT
DE19701141C1 (en) * 1997-01-16 1998-04-09 Hoechst Ag Gene construct for treatment of disease involving protease, particularly tumours and inflammation
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
CA2572921C (en) 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
WO2007046839A2 (en) 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
ES2620702B2 (en) * 2017-03-29 2017-12-18 Universidad De Cantabria Gene construction and its use in the treatment of cardiac fibrosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
DE3716722A1 (en) * 1987-05-19 1988-12-01 Hoechst Ag GENE TECHNOLOGICAL METHOD FOR PRODUCING ANGIOGENINES
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
FR2683226B1 (en) * 1991-10-30 1995-06-09 Univ Paris Curie CELLS TRAPED AGAINST ANTIGENS CAUSING DYSFUNCTION OF THE IMMUNE SYSTEM, MEDICINES FOR THE PREVENTION OR TREATMENT OF DISEASES INDUCED BY SUCH DYSFUNCTIONS.
WO1993013807A1 (en) * 1992-01-10 1993-07-22 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
EP0672132A1 (en) * 1992-03-03 1995-09-20 The Salk Institute For Biological Studies Receptor internalization signals
AU3968193A (en) * 1992-03-26 1993-10-21 Gensia, Inc. In vivo peptide therapy
BE1006437A3 (en) * 1992-12-10 1994-08-30 Company S A Z Nucleotide sequence for the treatment of cancer and infection.
WO1994021118A1 (en) * 1993-03-24 1994-09-29 The Uab Research Foundation Gene-therapy composition and method for treating carcinomas

Also Published As

Publication number Publication date
EP0802801A2 (en) 1997-10-29
JP2001520503A (en) 2001-10-30
WO1996021416A3 (en) 1996-10-10
WO1996021416A2 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
AU2212299A (en) Compositions and methods for the treatment of tumor
HUP0002760A3 (en) Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
AU2124397A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
IL105914A0 (en) Methods and compositions for in vivo gene therapy
AU1980995A (en) Methods and compositions for treatment of breast cancer
AU1926295A (en) Skin tanning compositions and methods for their preparation and use
AU5439996A (en) Compositions and methods for treating pain
AU4655296A (en) Compositions and methods for treating tumor cells
AU2113295A (en) Novel compositions and methods for water treatment
AU6872498A (en) Method and composition for skin treatment
AU1136297A (en) Methods and compositions for diagnosis of hyperhomocysteinemia
EP0758196A4 (en) Compositions and methods of treating tumors
AU4243397A (en) Methods for in vivo reduction of iron levels and compositions useful therefor
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU2821295A (en) Compositions and methods for the treatment of tumors
AU4608296A (en) Methods and compositions for treatment of solid tumors in vivo
AU1714697A (en) Method and composition for the treatment of osteoarthritis
IL141426A0 (en) Compositions and methods for the treatment of tumor
AU3768795A (en) Method and compositions for hair treatment
AU5333298A (en) Compositions and methods for tumour therapy
IL143212A0 (en) Compositions and methods for the treatment of tumor
AU3127795A (en) Composition and treatment for baldness
EP1018866A4 (en) Compositions and methods for the preservation of living tissues